| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Takashi Ueda, Shinya Ugawa, Yusuke Ishida, Shoichi Shimad. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors. European journal of pharmacology. vol 671. issue 1-3. 2012-03-01. PMID:21951966. |
although gm is far less potent at the dopamine receptor than aripiprazole at dopamine d(2l) receptors (ec(50)=4.4 μm for gm vs. ec(50)=56 nm for aripiprazole), gm and gm derivatives may comprise a new set of candidates for atypical antipsychotics. |
2012-03-01 |
2023-08-12 |
Not clear |
| Sridhar Natesan, Greg E Reckless, Karen B L Barlow, José N Nobrega, Shitij Kapu. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. The international journal of neuropsychopharmacology. vol 14. issue 9. 2012-01-24. PMID:21087552. |
while dopamine d2 receptor partial agonists (pas) have been long considered for treating schizophrenia, only one, aripiprazole, is clinically available for therapeutic use. |
2012-01-24 |
2023-08-12 |
rat |
| Jaqueline Nascimento Picada, Bruna de Jesus Neto Dos Santos, Franciele Celso, Jéssica Dias Monteiro, Kelly Morais Da Rosa, Leandro Rosa Camacho, Luciana Rodrigues Vieira, Taís Madelon Freitas, Tatiana Grasiela Da Silva, Viviane Minuzzo Pontes, Patrícia Pereir. Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice. Acta pharmacologica Sinica. vol 32. issue 10. 2012-01-24. PMID:21841809. |
aripiprazole is an antipsychotic agent to treat schizophrenia, which acts through dopamine d(2) partial agonism, serotonin 5-ht(1a) partial agonism and 5-ht(2a) antagonism. |
2012-01-24 |
2023-08-12 |
mouse |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. European journal of pharmacology. vol 668. issue 3. 2012-01-19. PMID:21816144. |
in vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine d2 and d3 receptors. |
2012-01-19 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. European journal of pharmacology. vol 668. issue 3. 2012-01-19. PMID:21816144. |
aripiprazole is the first dopamine d(2)/d(3) receptor partial agonist successfully developed and ultimately approved for treatment of a broad spectrum of psychiatric and neurological disorders. |
2012-01-19 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. European journal of pharmacology. vol 668. issue 3. 2012-01-19. PMID:21816144. |
aripiprazole's dopamine d(2) and serotonin 5-ht(1a) receptor partial agonist activities have been postulated to confer clinical efficacy without marked sedation, and a relatively favorable overall side-effect profile. |
2012-01-19 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. European journal of pharmacology. vol 668. issue 3. 2012-01-19. PMID:21816144. |
using aripiprazole's unique profile as a benchmark for new dopamine partial agonist development may facilitate discovery of new antipsychotics. |
2012-01-19 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. European journal of pharmacology. vol 668. issue 3. 2012-01-19. PMID:21816144. |
aripiprazole's intrinsic activity at dopamine d(2s) and d(2l) receptors was similar to that of opc-14857 and rgh-188; lower than that of dopamine and bifeprunox; and higher than that of ddm-rgh-188, sdz 208-912, sarizotan, and ndmc. |
2012-01-19 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. European journal of pharmacology. vol 668. issue 3. 2012-01-19. PMID:21816144. |
aripiprazole's intrinsic activity at dopamine d(3) ser-9 and d(3) gly-9 receptors was similar to that of opc-14857 and sarizotan; lower than that of dopamine, bifeprunox, rgh-188 and ddm-rgh-188; and higher than that of sdz 208-912 and ndmc. |
2012-01-19 |
2023-08-12 |
human |
| Yi-Wei Ye. Persistent hiccups associated with switching from risperidone to aripiprazole in a schizophrenic patient with cerebral palsy. Clinical neuropharmacology. vol 34. issue 4. 2011-12-07. PMID:21768798. |
aripiprazole with a partial agonist of dopamine d2 receptors and serotonin 1a receptors may play a crucial role in the pathophysiology of hiccups. |
2011-12-07 |
2023-08-12 |
Not clear |
| Ashwin A Patkar, Kathleen Peindl, Rajnish Mago, Paolo Mannelli, Prakash S Masan. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Primary care companion to the Journal of clinical psychiatry. vol 8. issue 2. 2011-11-10. PMID:16862232. |
aripiprazole is a novel atypical antipsychotic with partial agonism at dopamine d(2) and serotonin 5-ht(1a) receptors and antagonism at the 5-ht(2) receptors. |
2011-11-10 |
2023-08-12 |
Not clear |
| Laura S Boylan, Scott Hirsc. Motor worsening and tardive dyskinesia with aripiprazole in Lewy body dementia. BMJ case reports. vol 2009. 2011-11-10. PMID:21686897. |
aripiprazole (apz) is a novel antipsychotic agent which does not block dopamine (da) receptors but is rather a partial da agonist. |
2011-11-10 |
2023-08-12 |
Not clear |
| Caroline Biojone, Plínio C Casarotto, Leonardo B Resstel, Hélio Zangrossi, Francisco S Guimarães, Fabrício A Moreir. Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. Journal of psychopharmacology (Oxford, England). vol 25. issue 6. 2011-09-28. PMID:20699351. |
aripiprazole is a unique antipsychotic that seems to act as a partial agonist at dopamine d2-receptors, contrasting with other drugs in this class, which are silent antagonists. |
2011-09-28 |
2023-08-12 |
rat |
| E Liemburg, A Aleman, J Bous, K Hollander, H Knegterin. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry. vol 44. issue 3. 2011-09-27. PMID:21432752. |
this pilot study investigated the potentially therapeutic effects of the partial dopamine agonist aripiprazole on different negative symptoms. |
2011-09-27 |
2023-08-12 |
Not clear |
| Suwanna Vangveravong, Zhanbin Zhang, Michelle Taylor, Melissa Bearden, Jinbin Xu, Jinquan Cui, Wei Wang, Robert R Luedtke, Robert H Mac. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound. Bioorganic & medicinal chemistry. vol 19. issue 11. 2011-09-19. PMID:21536445. |
synthesis and characterization of selective dopamine d₂ receptor ligands using aripiprazole as the lead compound. |
2011-09-19 |
2023-08-12 |
Not clear |
| Suwanna Vangveravong, Zhanbin Zhang, Michelle Taylor, Melissa Bearden, Jinbin Xu, Jinquan Cui, Wei Wang, Robert R Luedtke, Robert H Mac. Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound. Bioorganic & medicinal chemistry. vol 19. issue 11. 2011-09-19. PMID:21536445. |
a series of compounds structurally related to aripiprazole (1), an atypical antipsychotic and antidepressant used clinically for the treatment of schizophrenia, bipolar disorder, and depression, have been prepared and evaluated for affinity at d(₂-like) dopamine receptors. |
2011-09-19 |
2023-08-12 |
Not clear |
| Mei Han, Xu-Feng Huang, Chao Den. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. The international journal of neuropsychopharmacology. vol 12. issue 7. 2011-09-06. PMID:19203411. |
aripiprazole also decreased dopamine transporter (dat) binding density in nac (for 1- and 12-wk treatment) and vta (1-wk treatment). |
2011-09-06 |
2023-08-12 |
Not clear |
| Mei Han, Xu-Feng Huang, Chao Den. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. The international journal of neuropsychopharmacology. vol 12. issue 7. 2011-09-06. PMID:19203411. |
selectively reducing dopamine synthesis in vta is a possible therapeutic mechanism for the long-term efficacy of aripiprazole in controlling schizophrenia symptoms with reduced extrapyramidal side-effects. |
2011-09-06 |
2023-08-12 |
Not clear |
| Kazuo Yamada, Yasuyuki Makihara, Yoshiki Imamur. Effectiveness of aripiprazole for medication overuse headache: a case report. Psychiatry and clinical neurosciences. vol 65. issue 3. 2011-08-30. PMID:21507137. |
aripiprazole, a dopamine d2 receptor partial agonist, has been used to treat schizophrenia and might be effective for alcohol dependence and craving. |
2011-08-30 |
2023-08-12 |
Not clear |
| Norio Yasui-Furukori, Hanako Furukori, Norio Sugawara, Akira Fujii, Sunao Kanek. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. Journal of clinical psychopharmacology. vol 30. issue 5. 2011-08-08. PMID:20814333. |
recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. |
2011-08-08 |
2023-08-12 |
Not clear |